Suspected herpes zoster-associated encephalitis during treatment with oral tofacitinib in alopecia universalis | Zendy

AnnaMarie Hosking | Zendy; Margit Juhász | Zendy; NatashaAtanaskova Mesinkovska | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Suspected herpes zoster-associated encephalitis during treatment with oral tofacitinib in alopecia universalis

Author(s) -

AnnaMarie Hosking,

Margit Juhász,

NatashaAtanaskova Mesinkovska

Publication year - 2018

Publication title -

international journal of trichology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.494

H-Index - 22

eISSN - 0974-9241

pISSN - 0974-7753

DOI - 10.4103/ijt.ijt_87_18

Subject(s) - medicine , alopecia universalis , tofacitinib , dermatology , adverse effect , shingles , rash , folliculitis , janus kinase inhibitor , concomitant , mucocutaneous zone , malignancy , surgery , alopecia areata , immunology , rheumatoid arthritis , virus , disease

Systemic administration of Janus kinase inhibitors (JAKis) is associated with adverse events, including serious infections, malignancy, and herpes zoster (HZ). Herein, we report a case of a 17-year-old male with alopecia universalis who developed suspected HZ-associated encephalitis (HZAE) during treatment with oral tofacitinib. Oral tofacitinib was immediately discontinued, and the patient was started on antiviral treatment. We present this case to highlight a serious complication that can arise with oral JAKi therapy. Physicians should have a high index of clinical suspicion for HZAE in any patient presenting with a vesicular rash and concomitant neurologic impairments while systemically immunosuppressed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research